Protalix Biotherapeutics, Inc. (PLX)
2.515
+0.04
(+1.41%)
USD |
NYAM |
Oct 27, 16:00
2.515
0.00 (0.00%)
After-Hours: 20:00
Protalix Biotherapeutics Enterprise Value : 167.65M for Oct. 26, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 26, 2026 | 167.65M |
| October 23, 2026 | 173.29M |
| October 22, 2026 | 174.90M |
| October 21, 2026 | 174.90M |
| October 20, 2026 | 180.54M |
| October 19, 2026 | 174.09M |
| October 16, 2026 | 178.93M |
| October 15, 2026 | 185.37M |
| October 14, 2026 | 178.12M |
| October 13, 2026 | 189.40M |
| October 12, 2026 | 191.82M |
| October 09, 2026 | 191.82M |
| October 08, 2026 | 185.37M |
| October 07, 2026 | 186.18M |
| October 06, 2026 | 187.79M |
| October 05, 2026 | 186.18M |
| October 02, 2026 | 186.18M |
| October 01, 2026 | 183.76M |
| September 30, 2026 | 190.21M |
| September 29, 2026 | 184.57M |
| September 28, 2026 | 184.57M |
| September 25, 2026 | 186.99M |
| September 24, 2026 | 189.40M |
| September 23, 2026 | 193.43M |
| September 22, 2026 | 196.65M |
| Date | Value |
|---|---|
| September 21, 2026 | 189.40M |
| September 18, 2026 | 184.57M |
| September 17, 2026 | 185.37M |
| September 16, 2026 | 183.76M |
| September 15, 2026 | 182.15M |
| September 14, 2026 | 191.01M |
| September 11, 2026 | 180.54M |
| September 10, 2026 | 187.79M |
| September 09, 2026 | 182.96M |
| September 08, 2026 | 181.35M |
| September 04, 2026 | 182.96M |
| September 03, 2026 | 178.93M |
| September 02, 2026 | 176.51M |
| September 01, 2026 | 176.51M |
| August 31, 2026 | 174.90M |
| August 28, 2026 | 172.48M |
| August 27, 2026 | 178.12M |
| August 26, 2026 | 167.65M |
| August 25, 2026 | 161.20M |
| August 24, 2026 | 162.01M |
| August 21, 2026 | 159.59M |
| August 20, 2026 | 159.59M |
| August 19, 2026 | 157.17M |
| August 18, 2026 | 156.37M |
| August 17, 2026 | 152.34M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Altimmune, Inc. | 108.37M |
| Taysha Gene Therapies, Inc. | 905.94M |
| Humacyte, Inc. | 97.42M |
| Agenus, Inc. | 527.17M |
| Amgen, Inc. | 283.68B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.777M |
| Revenue (Quarterly) | 19.90M |
| Total Expenses (Quarterly) | 16.12M |
| EPS Diluted (Quarterly) | 0.0458 |
| Gross Profit Margin (Quarterly) | 60.99% |
| Profit Margin (Quarterly) | 18.98% |
| Earnings Yield | 9.03% |
| Operating Earnings Yield | 11.33% |
| Normalized Earnings Yield | 9.026 |